Barclays
ACRS icon

Barclays’s Aclaris Therapeutics ACRS Stock Holding History

Barclays’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80.7K Sell
21,508
-121,906
-85% -$411K ﹤0.01% 4121
2025
Q4 		$432K Buy
143,414
+19,989
+16% +$50.5K ﹤0.01% 3929
2025
Q3 		$235K Sell
123,425
-32,912
-21% -$57.4K ﹤0.01% 4228
2025
Q2 		$222K Buy
156,337
+37,336
+31% +$50.5K ﹤0.01% 4205
2025
Q1 		$182K Buy
119,001
+103,800
+683% +$221K ﹤0.01% 4101
2024
Q4 		$37.7K Sell
15,201
-5,192
-25% -$12.9K ﹤0.01% 4818
2024
Q3 		$23.5K Sell
20,393
-19,852
-49% -$24.3K ﹤0.01% 4882
2024
Q2 		$44.3K Sell
40,245
-28,021
-41% -$32.9K ﹤0.01% 4250
2024
Q1 		$84.7K Sell
68,266
-107,653
-61% -$128K ﹤0.01% 4493
2023
Q4 		$185K Sell
175,919
-58,231
-25% -$178K ﹤0.01% 4452
2023
Q3 		$1.6M Buy
234,150
+148,761
+174% +$1.27M ﹤0.01% 2021
2023
Q2 		$885K Sell
85,389
-3,301
-4% -$29.9K ﹤0.01% 2384
2023
Q1 		$718K Buy
88,690
+45,880
+107% +$582K ﹤0.01% 2983
2022
Q4 		$674K Buy
42,810
+26,103
+156% +$420K ﹤0.01% 3099
2022
Q3 		$263K Sell
16,707
-5,262
-24% -$82.9K ﹤0.01% 3058
2022
Q2 		$307K Sell
21,969
-38,287
-64% -$537K ﹤0.01% 3180
2022
Q1 		$1.04M Sell
60,256
-40,262
-40% -$549K ﹤0.01% 2368
2021
Q4 		$1.46M Buy
100,518
+50,349
+100% +$763K ﹤0.01% 2576
2021
Q3 		$903K Buy
50,169
+38,402
+326% +$616K ﹤0.01% 2849
2021
Q2 		$205K Buy
11,767
+11,749
+65,272% +$267K ﹤0.01% 3540
2021
Q1 		$0 Hold
18
– – ﹤0.01% 4638
2020
Q4 		$0 Hold
18
– – ﹤0.01% 4846
2020
Q3 		$0 Sell
18
-8,276
-100% -$18.5K ﹤0.01% 5167
2020
Q2 		$13K Sell
8,294
-2,222
-21% -$2.98K ﹤0.01% 5283
2020
Q1 		$11K Sell
10,516
-73,337
-87% -$99.8K ﹤0.01% 5788
2019
Q4 		$159K Buy
83,853
+66,735
+390% +$111K ﹤0.01% 5194
2019
Q3 		$18K Sell
17,118
-5,897
-26% -$8.37K ﹤0.01% 6234
2019
Q2 		$50K Buy
23,015
+12,532
+120% +$68.3K ﹤0.01% 6088
2019
Q1 		$63K Buy
+10,483
New +$69.5K ﹤0.01% 5704
2018
Q4 		– Sell
-12,243
Closed -$178K – 6883
2018
Q3 		$178K Buy
12,243
+10,279
+523% +$176K ﹤0.01% 5100
2018
Q2 		$39K Sell
1,964
-4,414
-69% -$81.6K ﹤0.01% 5786
2018
Q1 		$111K Buy
6,378
+1,846
+41% +$39.1K ﹤0.01% 5308
2017
Q4 		$112K Sell
4,532
-2,925
-39% -$71.2K ﹤0.01% 5151
2017
Q3 		$192K Buy
7,457
+6,904
+1,248% +$185K ﹤0.01% 4458
2017
Q2 		$15K Sell
553
-5,055
-90% -$137K ﹤0.01% 5905
2017
Q1 		$167K Buy
5,608
+258
+5% +$7.44K ﹤0.01% 4481
2016
Q4 		$145K Buy
5,350
+5,197
+3,397% +$133K ﹤0.01% 4468
2016
Q3 		$4K Buy
+153
New +$3.25K ﹤0.01% 6054
2016
Q1 		– Sell
-1,000
Closed -$26K – 6110
2015
Q4 		$26K Buy
+1,000
New +$19.5K ﹤0.01% 5102

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Barclays's ACRS Position: Q1 2026 in Review

Barclays reduced its Aclaris Therapeutics (ACRS) stake by 85% in Q1 2026, selling an estimated $411K and leaving 21,508 shares worth $80.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4121.

Barclays first reported a position in ACRS in Q4 2015 and has held it in 39 quarters since. The position peaked at $1.6M in Q3 2023. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Barclays held 21,508 shares of Aclaris Therapeutics worth $80.7K as of Q1 2026.
  • Barclays sold 121,906 Aclaris Therapeutics shares in Q1 2026, an estimated $411K.
  • Aclaris Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4121 holding.
  • Barclays first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 39 quarters since.
  • Barclays's Aclaris Therapeutics position peaked at $1.6M in Q3 2023.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.